Stratasys Launches TrueDent in Europe, Bringing the Benefits of Monolithic Digital Dentures to Dental Labs, Dentists, and Patients

Rhea-AI Summary

Stratasys (NASDAQ: SSYS) has announced the European launch of its TrueDent-D™ resin as a CE Mark Class I medical device, following its successful U.S. debut in 2023. Over 30 customers have committed to implementing the solution in Q1 2025.

The European denture market is projected to grow from USD 2.19 billion in 2023 to USD 2.45 billion by 2028. TrueDent offers a digital workflow that enables dental labs to produce customized dentures at less than half the cost of traditional methods. The J5 DentaJet™ printer can produce over 30 full monolithic, multi-shade dentures per print job.

The solution eliminates 27+ manual touchpoints per print and provides unique capabilities for producing identical duplicate dentures. The digital denture market share in the U.S. has increased from 5% in 2022 to 11% in 2024, indicating growing adoption of digital workflows in dental laboratories.

Positive

• Over 30 new customers committed for Q1 2025 implementation
• Production costs less than half of traditional methods
• Capacity to produce 30+ dentures per print job
• Eliminates 27+ manual touchpoints in production
• Addresses growing market projected to reach $2.45B by 2028

Negative

• None.

Insights

Medical Technology Analyst

The European launch of TrueDent represents a strategic market expansion in the $2.19 billion European denture market. The technology's ability to produce 30+ dentures per print job at less than half the traditional production cost presents a compelling value proposition. The pre-launch commitment from 30+ customers in Q1 2025 indicates strong market validation.

The projected market growth to $2.45 billion by 2028 and the rise in digital denture production from 5% to 11% in the U.S. suggests significant revenue potential. The solution's unique capability to produce identical replicas efficiently addresses both the growing patient demand and the industry's labor shortage challenges.

Particularly noteworthy is the elimination of 27 manual touchpoints and the unattended workflow, which directly impacts operational efficiency and scalability. This operational leverage could significantly improve profit margins for dental labs while creating recurring revenue streams through the backup denture business model.

Healthcare Market Strategist

The timing of this European expansion aligns perfectly with three critical market dynamics: an aging population, increasing adoption of digital dentistry and persistent labor shortages in dental laboratories. The CE Mark Class I medical device certification removes regulatory barriers in key European markets, enabling rapid market penetration.

The case study from Express Dental Laboratories, producing 225 dental appliances daily, demonstrates the solution's scalability and real-world validation. This throughput capability, combined with the 10% prevalence rate of edentulism in adults over 50, positions Stratasys to capture significant market share in the growing digital dentistry segment.

The business model innovation of offering identical backup dentures creates a new revenue stream that didn't exist in the traditional denture market. This differentiator could drive both initial adoption and long-term customer retention while establishing recurring revenue patterns.

TrueDent-D™ resin is now available in major European markets that require CE marking, with strong customer interest already building

EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)-- Stratasys (NASDAQ: SSYS) has declared that its TrueDent-D™ resin is available for sale in Europe as a CE Mark Class I medical device. This milestone enables the sale of its TrueDent™ monolithic multi-shade digital denture solution in European countries that require CE marking.

Stratasys Launches TrueDent™ in Europe (Photo: Business Wire)

Following its successful debut in the United States in 2023, TrueDent is now set to deliver a scalable, efficient, and high-quality solution for denture production for dental labs and clinicians across Europe. Interest in the TrueDent-D resin is already strong, with more than 30 customers committed to onboarding in Q1 2025.

According to a recent iData report¹, the demand for denture solutions in Europe continues to grow as the region’s opportunity for dentures is projected to expand from USD 2.19 billion in 2023 to USD 2.45 billion by 2028. The TrueDent denture solution by Stratasys is designed to answer this demand with a fully digital workflow that enables dental labs to produce customized dentures efficiently, offering dentists and patients an improved outcome in fewer appointments. Stratasys estimates the total cost for a lab to produce a TrueDent denture is less than half of those produced by traditional means. One Stratasys J5 DentaJet™ printer can produce more than 30 full monolithic, multi-shade dentures per print job, a figure unmatched in the industry.

A key feature is the ability to print a duplicate denture with a click of a button enabling clinicians to quickly provide a spare or a backup for their patients. TrueDent is the only solution in the world that can produce identical dentures when needed, offering not just fit, form and function, but also aesthetics. This capability creates potential for new business models, allowing customers to scale production without increasing costs or labor requirements.

“The TrueDent solution has transformed our denture business,” said Tra’ Chambers, Owner of Express Dental Laboratories, a leading U.S. TrueDent customer. “The streamlined digital workflow and precision allows us to produce up to 225 dental appliances per day while delivering high fidelity, highly aesthetic appliances to our customers. The Stratasys TrueDent offering has elevated the level of care we can provide, saving time and costs for both clinicians and patients.”

Edentulism, the condition of being without natural teeth, affects over 267.5 million people globally, including a prevalence rate exceeding 10% among adults over 50 in many regions. The percentage of denture cases produced using digital methods in the U.S. has risen from 5% in 2022 to 11% in 2024. Similarly, European dental labs are increasingly adopting digital workflows to address labor shortages and meet patient needs faster and with greater accuracy.

The TrueDent denture solution elevates the challenges faced by labs that are limited by current fabrication methods that often involve the need for manual assembly by skilled craftspeople. TrueDent is already proving its value in the U.S., where it has transformed the way dental labs operate. By implementing an unattended streamlined digital workflow, TrueDent eliminates 27 or more manual touchpoints per print, reduces chair time for dental professionals and patients, and enhances patient satisfaction with high-aesthetic, true-to-design fit, form and function appliances.

“We are thrilled to bring TrueDent-D to Europe,” said Erez Ben Zvi, Vice President of Healthcare at Stratasys. “Our monolithic TrueDent denture solution combines high fidelity, aesthetics, and production scalability, while reducing labor costs and enabling exact reproductions. There is growing excitement across the region for this innovative solution, which not only improves the experience for dental professionals but also elevates the standard of care for patients.”

For more information about the TrueDent digital denture application, visit the Stratasys TrueDent page.

¹ – iData Europe Market Report Suite for Dental Prosthetics, February 2024

About Stratasys

Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products, and healthcare. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, X/Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including Stratasys’ websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

Stratasys, TrueDent, TrueDent-D and J5 DentaJet are trademarks or registered trademarks of Stratasys Ltd. and/or its affiliates. All other trademarks are the property of their respective owners.

Note Regarding Forward-Looking Statement

The statements in this press release relating to Stratasys’ beliefs regarding the benefits consumers will experience from using the TrueDent-D resin, it’s time of general ability and other statements in this press release are forward-looking statements reflecting management's current expectations and beliefs. These forward-looking statements are based on current information that is, by its nature, subject to rapid and even abrupt change. Due to risks and uncertainties associated with Stratasys' business, actual results could differ materially from those projected or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the degree of our success at introducing new or improved products and solutions that gain market share; the degree of growth of the 3D printing market generally; the impact of potential shifts in the prices or margins of the products that we sell or services that we provide, including due to a shift towards lower-margin products or services; the impact of competition and new technologies; potential further charges against earnings that we could be required to take due to impairment of additional goodwill or other intangible assets; to the extent of our success at successfully consummating acquisitions or investments in new businesses, technologies, products or services; potential changes in our management and board of directors; global market, political and economic conditions, and in the countries in which we operate in particular; risks related to infringement of our intellectual property rights by others or infringement of others' intellectual property rights by us; the extent of our success at maintaining our liquidity and financing our operations and capital needs; the impact of tax regulations on our results of operations and financial condition; and other risk factors set forth under the caption “Risk Factors” in Stratasys’ most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 11th, 2024. Readers are urged to carefully review and consider the various disclosures made throughout our 2023 Annual Report and our other reports filed with or furnished to the SEC, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. Any guidance provided, and other forward-looking statements made, in this press release are made as of the date hereof, and Stratasys undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114856677/en/

Media and Investor contacts:

Stratasys Corporate, North America & EMEA

Chris Reese

chris.reese@stratasys.com

+1 651 357 0877

Stratasys Corporate, Israel & EMEA

Erik Snider

Erik.Snider@stratasys.com

+972 74 745 6053

Investor Relations

Yonah Lloyd

Yonah.Lloyd@stratasys.com

+972 74 745 4919

Source: Stratasys

FAQ

What is the projected market size for dentures in Europe by 2028 for SSYS?

According to an iData report, the European denture market is projected to grow from USD 2.19 billion in 2023 to USD 2.45 billion by 2028.

How many customers have committed to implementing SSYS TrueDent in Q1 2025?

More than 30 customers have committed to onboarding TrueDent in Q1 2025.

What is the production capacity of SSYS J5 DentaJet printer for TrueDent dentures?

One Stratasys J5 DentaJet printer can produce more than 30 full monolithic, multi-shade dentures per print job.

How much cost reduction does SSYS TrueDent offer compared to traditional denture production?

Stratasys estimates the total cost for a lab to produce a TrueDent denture is less than half of those produced by traditional means.

What is the current digital denture production rate in the US market for SSYS?

The percentage of denture cases produced using digital methods in the U.S. has increased from 5% in 2022 to 11% in 2024.